摘要
目的探讨miR-134在乳腺癌中的表达及临床意义,分析其表达与上皮-间质转化(epithelial-mesenchymal transition,EMT)标志物的相关性。方法采用原位分子杂交法检测97例乳腺癌组织中miR-134的表达,同时应用免疫组化Max Vision两步法检测E-cadherin、N-cadherin、vimentin的表达,并分析三者表达与临床病理特征的关系。结果 miR-134在乳腺癌中的阳性率随组织学分级的升高而降低,其表达与HER-2表达呈负相关。miR-134的阳性率随E-cadherin表达下调及N-cadherin、vimentin表达上调而降低;E-cadherin在乳腺癌中表达下调以及N-cadherin、vimentin在乳腺癌中表达上调均与组织学分级升高、淋巴结转移和HER-2阳性以及ER、PR阴性有关。结论 miR-134在乳腺癌组织中的表达随肿瘤恶性程度的升高而下调,并与EMT关系密切,是乳腺癌的潜在生物学标志物。
Purpose To investigate the expression of miR-134 in breast carcinoma and its clinical significance,and to analyze the as-sociation between its expression with bio-markers of epithelial-mesenchymal transition（ EMT）. Methods The expression of miR-134 in 97 breast cancer samples was detected by in situ hybridization and the expression of E-cadherin,N-cadherin,and vimentin was de-tected by MaxVision two-step method of immunohistochemistry,to analyze the relationship between their expression and clinicopatholog-ical characteristics. Results The expression of miR-134 in breast cancer was negatively associated with higher histological grade, HER-2 overexpression,low expression of E-cadherin as well as high expression of N-cadherin and vimentin. Both low-expression of E-cadherin and up-expression of N-cadherin and vimentin in breast cancer were positively correlated with higher histological grade,lymph node involvement and HER-2 overexpression,while negatively associated with the expression of ER and PR. Conclusion The expres-sion of miR-134 in breast cancer tissue is negatively related to both the malignant progression and EMT,indicating that it might be a potential bio-marker for breast cancer.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2015年第6期648-651,共4页
Chinese Journal of Clinical and Experimental Pathology
基金
国家自然科学基金(81372476
81172533)
